Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Prostate Cancer

  Free Subscription


15.12.2025

1 AJR Am J Roentgenol
3 BJU Int
2 BMC Cancer
1 BMC Urol
1 Cancer Imaging
2 Cancer Lett
1 Cancer Res
1 Eur Radiol
9 Eur Urol
1 Int J Oncol
3 Int J Urol
1 Invest Radiol
1 J Natl Cancer Inst
1 J Nucl Med
3 J Urol
2 Magn Reson Imaging
1 PLoS One
1 Proc Natl Acad Sci U S A
6 Prostate
1 Radiol Imaging Cancer
2 Radiology
2 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. ABREU-GOMEZ J, Eberhardt SC, Chapin BF, Fennessy FM, et al
    MRI for Prostate Cancer Local Staging: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2025 Dec 10. doi: 10.2214/AJR.25.33846.
    PubMed         Abstract available


    BJU Int


  2. Prostate cancer: screening, diagnosis and treatment.
    BJU Int. 2026;137:10-11.
    PubMed        

  3. CRISAFI D, Jiang J, Bolton D, Ischia J, et al
    What are we missing? Identifying clinically significant prostate cancer among patients with low PSA: the utility of the free-to-total PSA ratio.
    BJU Int. 2025 Dec 8. doi: 10.1111/bju.70110.
    PubMed        

  4. MARMIROLI A, Di Bello F, Penaranda NR, Longoni M, et al
    Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy.
    BJU Int. 2026;137:209-215.
    PubMed         Abstract available


    BMC Cancer

  5. ABDELRAHMAN M, Shafaa MW, Abdelrahman H, Ibrahim M, et al
    Positively charged liposomal beta-carotene enhances irradiation-induced cytotoxicity against prostate carcinoma cells: an in-vitro study.
    BMC Cancer. 2025 Dec 10. doi: 10.1186/s12885-025-15244.
    PubMed        

  6. RAEISVANDI A, Omidi S, Javaheri M, Moradi H, et al
    Updated dose-response meta-analysis of sexual activity and prostate cancer risk.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15410.
    PubMed         Abstract available


    BMC Urol

  7. WANG C, Wang G, Xiao L, Du H, et al
    Preoperative predictors about lymph node metastasis and biochemical recurrence in high-risk prostate cancer patients: a clinic pathological retrospective study.
    BMC Urol. 2025 Dec 5. doi: 10.1186/s12894-025-01999.
    PubMed        


    Cancer Imaging

  8. BERG EK, Kunte SC, Zahner J, Holzgreve A, et al
    PSMA expression assessed by [(18)F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.
    Cancer Imaging. 2025;25:136.
    PubMed         Abstract available


    Cancer Lett

  9. GUAN Y, Cao F, Luo Y, Li J, et al
    High-fat diet induced ECM remodeling attenuates chemosensitivity in prostate cancer via activating Piezo1-dependent mitochondria-ER contacts.
    Cancer Lett. 2025 Dec 9:218204. doi: 10.1016/j.canlet.2025.218204.
    PubMed         Abstract available

  10. MAK CSL, Zhu M, Fu J, Liang X, et al
    KDM4A promotes NEPC progression through regulation of MYC expression.
    Cancer Lett. 2026;638:218184.
    PubMed         Abstract available


    Cancer Res

  11. KITTANE S, Ladewig E, Li T, Love JR, et al
    The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer.
    Cancer Res. 2025 Dec 11. doi: 10.1158/0008-5472.CAN-25-2053.
    PubMed         Abstract available


    Eur Radiol

  12. LANGKILDE F, Gren M, Wallstrom J, Kuczera S, et al
    Evaluation of AI for prostate cancer detection in biparametric-MRI screening population data.
    Eur Radiol. 2025 Dec 8. doi: 10.1007/s00330-025-12198.
    PubMed         Abstract available


    Eur Urol

  13. TILKI D, Chen MH, D'Amico AV
    Re: Alexander B.C.D. Ng, Aqua Asif, Ridhi Agarwal, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA 2025;334:1170-9.
    Eur Urol. 2025 Dec 12:S0302-2838(25)04853-5. doi: 10.1016/j.eururo.2025.
    PubMed        

  14. GANDAGLIA G, Briganti A, Catto JW, Cornford P, et al
    Re: Rebecca Voelker. What Is Prostate Cancer? JAMA. In press. https://doi.org/10.1001/jama.2025.10177.
    Eur Urol. 2025 Dec 12:S0302-2838(25)04849-3. doi: 10.1016/j.eururo.2025.09.4181.
    PubMed        

  15. COZZI S, Zilli T
    Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://
    Eur Urol. 2025 Dec 12:S0302-2838(25)04850-X. doi: 10.1016/j.eururo.2025.
    PubMed        

  16. PATTOU M, Peyrottes A, Long-Depaquit T, Tokarski E, et al
    Re: Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis. The PRIME Diagnostic Clinical Trial.
    Eur Urol. 2025 Dec 10:S0302-2838(25)04841-9. doi: 10.1016/j.eururo.2025.
    PubMed        

  17. HO A, Sachdev S
    Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://
    Eur Urol. 2025 Dec 8:S0302-2838(25)04843-2. doi: 10.1016/j.eururo.2025.
    PubMed        

  18. BRIERS E
    SPARC: The Importance for Patients with Prostate Cancer.
    Eur Urol. 2025 Dec 6:S0302-2838(25)04837-7. doi: 10.1016/j.eururo.2025.
    PubMed        

  19. RATNAKUMARAN R, Brand DH, Sasitharan A, Mohajer J, et al
    Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study.
    Eur Urol. 2026;89:71-79.
    PubMed         Abstract available

  20. KISHAN AU, Juarez Casillas JE, Sargos P, Kalbasi TR, et al
    Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.
    Eur Urol. 2026;89:12-17.
    PubMed         Abstract available

  21. MARVASO G, Francolini G, Achard V, Gomez-Iturriaga A, et al
    Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.
    Eur Urol. 2026;89:5-7.
    PubMed         Abstract available


    Int J Oncol

  22. HUANG Y, Mao J, Li X
    Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).
    Int J Oncol. 2026;68:15.
    PubMed         Abstract available


    Int J Urol

  23. OKAMOTO K, Ozawa Y, Kayaba T, Koike S, et al
    Does Accessory Pudendal Artery Preservation Increase the Risk of Positive Surgical Margins in Robot-Assisted Radical Prostatectomy?
    Int J Urol. 2025;32:1762-1770.
    PubMed         Abstract available

  24. URABE F
    Editorial Comment on "DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade".
    Int J Urol. 2025 Dec 8. doi: 10.1111/iju.70311.
    PubMed        

  25. WATANABE R
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Dec 10. doi: 10.1111/iju.70317.
    PubMed        


    Invest Radiol

  26. SCHEENEN TWJ, Fortuin AS, Oprea-Lager DE, de Rooij M, et al
    The Current and Future Role of MRI and PSMA-PET/CT in Diagnosing Oligometastatic Prostate Cancer.
    Invest Radiol. 2025 Dec 8. doi: 10.1097/RLI.0000000000001264.
    PubMed         Abstract available


    J Natl Cancer Inst

  27. SCHENK JM, Gulati R, Beatty SJ, Plymate S, et al
    Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study.
    J Natl Cancer Inst. 2025;117:2682-2686.
    PubMed         Abstract available


    J Nucl Med

  28. MAURER A, Muehlematter UJ, Sivakumar T, Mortezavi A, et al
    High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?
    J Nucl Med. 2025 Dec 4:jnumed.125.271318. doi: 10.2967/jnumed.125.271318.
    PubMed         Abstract available


    J Urol

  29. SHORE ND, Gleave M, De Giorgi U, Rannikko A, et al
    Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial.
    J Urol. 2025 Dec 9:101097JU0000000000004890. doi: 10.1097/JU.0000000000004890.
    PubMed         Abstract available

  30. SHORE ND, De Giorgi U, Tutrone RF, Bailen JL, et al
    Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints.
    J Urol. 2025 Dec 5:101097JU0000000000004879. doi: 10.1097/JU.0000000000004879.
    PubMed         Abstract available

  31. WAISMAN MALARET AJ, Feustel PJ, Gaba F, Bakbak H, et al
    Participant-Reported Outcome Measures After Transrectal and Transperineal Prostate Biopsy in a Randomized Clinical Trial.
    J Urol. 2026;215:20-29.
    PubMed         Abstract available


    Magn Reson Imaging

  32. CORATO V, Vingiani V, Proner B, Martirosian P, et al
    Arterial spin labelling as a contrast-free alternative to dynamic contrast enhancement for the evaluation of peripheral zone prostatic lesions on MRI.
    Magn Reson Imaging. 2025 Nov 19:110575. doi: 10.1016/j.mri.2025.110575.
    PubMed         Abstract available

  33. WU D, Tang Z
    Application value of prostate-specific antigen density combined with multiparametric MRI in early diagnosis of prostate cancer.
    Magn Reson Imaging. 2025 Dec 11:110593. doi: 10.1016/j.mri.2025.110593.
    PubMed         Abstract available


    PLoS One

  34. WO Q, Shou J, Shi J, Shi L, et al
    Identification and validation of palmitoylation-related signature genes based on machine learning for prostate cancer.
    PLoS One. 2025;20:e0338407.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  35. ERSOY-FAZLIOGLU B, Lingadahalli S, Altintas UB, Cingoz A, et al
    Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2500327122.
    PubMed         Abstract available


    Prostate

  36. MCELYEA KC, Purtell JP, Supernois AK, Rose CM, et al
    Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns.
    Prostate. 2025 Dec 7. doi: 10.1002/pros.70103.
    PubMed         Abstract available

  37. STOYANOVA T, Priceman SJ, Ross AE, Tran PT, et al
    Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2025 Dec 7. doi: 10.1002/pros.70102.
    PubMed         Abstract available

  38. KO HK, Foertsch RL, Shi K, Pittsenbarger J, et al
    Prostate Cancer Cells With the AR-Low and EMT-High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors.
    Prostate. 2025 Dec 9. doi: 10.1002/pros.70100.
    PubMed         Abstract available

  39. BRAY G, Bahadori A
    Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
    Prostate. 2025 Dec 12. doi: 10.1002/pros.24506.
    PubMed         Abstract available

  40. CARSKADON S, Williamson S, Jyothilingam S, Gupta N, et al
    Mapping Molecular Diversity in Prostate Cancer With a Combined Multiplex IHC and RNA-ISH Assay.
    Prostate. 2025 Dec 12. doi: 10.1002/pros.70108.
    PubMed         Abstract available

  41. ISHIDA M, Narita S, Sato H, Sekine Y, et al
    Androgen-Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High-Risk Localized Prostate Cancer.
    Prostate. 2025 Dec 13. doi: 10.1002/pros.70109.
    PubMed         Abstract available


    Radiol Imaging Cancer

  42. FIROOZEH N, Mastrodicasa D, Behr S, Muglia VF, et al
    Zero-Shot PI-RADS Version 2.1 Scoring with ChatGPT-4 Turbo and Llama 3: Diagnostic Performance and Agreement with Abdominal Radiologists.
    Radiol Imaging Cancer. 2026;8:e250119.
    PubMed         Abstract available


    Radiology

  43. ULANER GA, Bassett JC, Reddy R, Thomsen B, et al
    (61)Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of (61)Cu-labeled PET Radiotracers.
    Radiology. 2025;317:e251151.
    PubMed         Abstract available

  44. WOO S, Masci B, Rowe SP, Caruso D, et al
    Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET.
    Radiology. 2025;317:e250701.
    PubMed         Abstract available


    Urology

  45. AHMAD Z
    Integration of Wearable Digital Urinary Sensors and Patient-reported Outcomes to Monitor Post-prostatectomy Incontinence: A Prospective Pilot Study.
    Urology. 2025;206:25-30.
    PubMed         Abstract available

  46. WOODLE T, Hebert K, Kurtzman JT, Horns JJ, et al
    Defining Long-Term Prostate Cancer Treatment Patterns and Adverse Urologic Events: A Methodological Framework and Patient Outcomes Using the Utah Population Database.
    Urology. 2025 Dec 4:S0090-4295(25)01352-4. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.